恒信東方(300081.SZ):VR遊戲產品《Drakheir》(暫定名)預計下半年正式發佈推出市場
格隆匯7月18日丨有投資者向恒信東方(300081.SZ)提問,“公司的Drakheir遊戲在meta測試效果如何?什麼時候正式發佈推出市場?在蘋果頭顯上什麼時候開始測試?”
恒信東方回覆稱,公司VR遊戲產品《Drakheir》(暫定名)目前正在Quest平台第三方應用平台Sidequest公測,並根據用户反饋情況持續優化,相關研發工作在持續推進,預計下半年正式發佈推出市場。公司將視市場需求和業務需要考慮是否將《Drakheir》移植到蘋果Vision Pro頭顯。敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.